

FOR IMMEDIATE RELEASE
September 17, 2002

Biowave Awarded Best in Class Early Stage Venture Company at Connecticut
Venture Group's Annual Summit

Stamford, CT;
Stamford Marriott

Connecticut Venture Group's Annual Summit:
BUILDING BUSINESS VENTURES IN CONNECTICUT

In front of John Rowland, Governor of Connecticut, 450 people, 100 Venture Capital firms, and a leading Venture Capital Panel, Biowave was chosen out of 50 companies attending the Summit as the Best in Class Early Stage Venture Company.

The Venture Capitalists attending the summit visited with each attending Company, and at the end of the event, selected Biowave as the Best in Class Early Stage Venture Company. Brad Siff, President and CEO of Biowave commented, "We are delighted to receive this recognition from such a prestigious group."

Biowave has developed a non-invasive, medical device that uses proprietary technology to send an electronic signal into deep tissue in the body blocking the transmission of pain. The device provides results similar to implantable neuromodulation devices in a non-invasive procedure at a fraction of the cost. Controlled, double-blinded clinical studies conducted under institutional review board approval at Weill Medical College at Cornell University have shown that after having a 20-minute treatment with the Biowave device, patients have an average 80% reduction in pain and a dramatic increase in range of motion. In addition, following the treatment, patients have residual pain relief and an increase in range of motion for up to 24 hours. Biowave intends to request approval from the FDA in the near future for marketing its pain management system in the U.S.

For more information, contact:
Bradford Siff
President & CEO
Biowave Corporation
16 Knight Street
Norwalk, CT 06851

email: bradsiff@biowave.com
tel: 203-855-8610
cell: 203-216-2273
fax: 203-855-8789